Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2013-03-01 Regulatory Filings
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2013
Regulatory Filings
2013-03-01 English
FORM 8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is a current report filed with the SEC to disclose material events or agreements. The text describes the entry into a material definitive agreement (a License Agreement) between Titan Pharmaceuticals and Braeburn Pharmaceuticals. It provides detailed terms of the agreement, including payments, royalties, and termination clauses. The document also includes an explanatory note and references exhibits such as the License Agreement and a press release. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or other categories related to financial results or governance changes. The document is a regulatory filing reporting a material contract event, which fits the category of Regulatory Filings (RNS). The length (8694 characters) and content confirm it is a substantive filing, not just a brief announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2013-02-28 English
FORM 4
Director's Dealing
2013-02-27 English
FORM 4
Director's Dealing
2013-02-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes an announcement about the FDA advisory committee review of a New Drug Application and references an attached press release. The document length is short (2466 characters), and it primarily serves as an announcement rather than a detailed financial report or other specific filing type. It does not contain financial statements, management discussion, or detailed data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-02-27 English
Major Shareholding Notification 2013
Major Shareholding Notification
2013-02-14 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.